Radiprodil is under clinical development by Neurvati Neurosciences and currently in Phase II for Tuberous Sclerosis. According to GlobalData, Phase II drugs for Tuberous Sclerosis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Radiprodil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Radiprodil overview

Radiprodil is under development for the treatment of GRIN-related disorder, tuberous sclerosis complex and focal cortical dysplasia. It acts by targeting NMDA-2B receptor. It is administered in the from of granules and suspension through oral route.

Neurvati Neurosciences overview

Neurvati Neurosciences (Neurvati) identify and develops high-potential technologies to address a range of medical needs to treat neurological and psychiatric disorders. The company’s collaborative model supports rapid late-stage development of treatments by pre-clinical and clinical data across neuroscience landscape. It advances projects based on fundamental analysis of the science, clinical data, regulatory path, and commercial viability. The company was funded by Backstone Life Sciences. Neurvati is headquartered in New York, the US.

For a complete picture of Radiprodil’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.